Status:
TERMINATED
Promoting Medications for Alcohol Use Disorder on the General Medicine Service
Lead Sponsor:
Yale University
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
Brief Summary
Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol...
Detailed Description
Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol...
Eligibility Criteria
Inclusion
- Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the 9-5, 4-6 and 4-7 general medicine services at Yale New Haven Hospital. The intervention will be conducted on 9-5, 4-6 and 4-7 general medicine services at Yale New Haven Hospital.
Exclusion
- Physicians trainees (student, residents, and fellows) will be excluded.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04287790
Start Date
January 1 2020
End Date
February 1 2021
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale School of Medicine
New Haven, Connecticut, United States, 06520